- Home
- XPEL vs SPRY Comparison
XPEL vs SPRY Comparison
Compare XPEL & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XPEL | SPRY |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 946.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | XPEL | SPRY |
|---|---|---|
| Price | $50.55 | $10.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $31.25 |
| AVG Volume (30 Days) | 307.8K | ★ 2.2M |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $461,460,000.00 | $142,772,000.00 |
| Revenue This Year | $16.20 | N/A |
| Revenue Next Year | $11.28 | $124.59 |
| P/E Ratio | $29.91 | ★ N/A |
| Revenue Growth | 10.29 | ★ 5459.66 |
| 52 Week Low | $24.25 | $6.66 |
| 52 Week High | $51.64 | $18.90 |
Technical Indicators
Market Signals| Indicator | XPEL | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 80.30 | 58.86 |
| Support Level | $48.54 | $9.77 |
| Resistance Level | $50.00 | $11.45 |
| Average True Range (ATR) | 1.47 | 0.66 |
| MACD | 0.09 | 0.25 |
| Stochastic Oscillator | 85.24 | 72.24 |
Price Performance
Historical ComparisonAbout XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.